About: Asenapine

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Asenapine Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	http://linked.opendata.cz/ontology/drugbank/Drug
http://linked.open...gbank/description	Developed by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with bipolar disorder. Asenapine also belongs to the dibenzo-oxepino pyrrole class. It is also for severe post-traumatic stress disorder nightmares in soldiers as an off-label use. FDA approved on August 13, 2009. (en)
http://linked.open...y/drugbank/dosage	http://linked.opendata.cz/resource/drugbank/dosage/271B4AAD-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B4AAC-363D-11E5-9242-09173F13E4C5
http://linked.open...generalReferences	# Huang M, Li Z, Dai J, Shahid M, Wong EH, Meltzer HY: Asenapine Increases Dopamine, Norepinephrine, and Acetylcholine Efflux in the Rat Medial Prefrontal Cortex and Hippocampus. Neuropsychopharmacology. 2008 Apr 16;. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18418367 # Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologicagent with a unique human receptor signature. J Psychopharmacol. 2008 Feb 28;. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18308814 # Franberg O, Wiker C, Marcus MM, Konradsson A, Jardemark K, Schilstrom B, Shahid M, Wong EH, Svensson TH: Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. Psychopharmacology (Berl). 2008 Feb;196(3):417-29. Epub 2007 Oct 17. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17940749 # Fagiolini A, Forgione RN, Morana B, Maccari M, Goracci A, Bossini L, Pellegrini F, Cuomo A, Casamassima F: Asenapine for the treatment of manic and mixed episodes associated with bipolar I disorder: from clinical research to clinical practice. Expert Opin Pharmacother. 2013 Mar;14(4):489-504. doi: 10.1517/14656566.2013.765859. Epub 2013 Jan 29. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/23356509 (en)
http://linked.open...gy/drugbank/group	approved (en)
http://linked.open...drugbank/halfLife	24 hours (range of 13.4 - 39.2 hours) (en)
http://linked.open...ugbank/indication	Used for treatment in psychosis, schizophrenia and schizoaffective disorders, manic disorders, and bipolar disorders as monotherapy or in combination. (en)
sameAs	Asenapine
Title	Asenapine (en)
adms:identifier	http://linked.opendata.cz/resource/drugbank/drug/DB06216/identifier/chebi/71253 http://linked.opendata.cz/resource/drugbank/drug/DB06216/identifier/chemspider/10128588 http://linked.opendata.cz/resource/drugbank/drug/DB06216/identifier/drugbank/DB06216 http://linked.opendata.cz/resource/drugbank/drug/DB06216/identifier/kegg-drug/D02995 http://linked.opendata.cz/resource/drugbank/drug/DB06216/identifier/national-drug-code-directory/0052-2139-03 http://linked.opendata.cz/resource/drugbank/drug/DB06216/identifier/pubchem-compound/11954293 http://linked.opendata.cz/resource/drugbank/drug/DB06216/identifier/pubchem-substance/17397151 http://linked.opendata.cz/resource/drugbank/drug/DB06216/identifier/wikipedia/Asenapine
http://linked.open...mechanismOfAction	Asenapine is an atypical antipsychotic multireceptor neuroleptic drug which shows strong 5HT2A (serotonin) and D2 (dopamine) receptor antagonism, which has been shown to enhance dopamine (DA) and acetylcholine (Ach) efflux in rat brains. Asenapine may improve cognitive function and negative symptoms in patients with schizophrenia. (en)
http://linked.open...y/drugbank/patent	http://linked.opendata.cz/resource/drugbank/patent/5763476 http://linked.opendata.cz/resource/drugbank/patent/7741358
http://linked.open...outeOfElimination	Urine (50%) and feces (50%) (en)
http://linked.open.../drugbank/synonym	Saphris (en)
http://linked.open...umeOfDistribution	20-25 L/kg (en)
http://linked.open.../drug/hasAHFSCode	http://linked.opendata.cz/resource/AHFS/28-16-08-04
http://linked.open...k/foodInteraction	Avoid water and food for at least 10 minutes post administration of asenapine (en)
http://linked.open...nk/proteinBinding	95% protein bound (en)
http://linked.open...ogy/drugbank/salt	(en)
http://linked.open...ynthesisReference	"DrugSyn.org":http://www.drugsyn.org/Asenapine.htm (en)
foaf:page	http://www.drugs.com/mtm/asenapine.html http://www.rxlist.com/saphris-drug.htm
http://linked.open...ugbank/IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B4AAF-363D-11E5-9242-09173F13E4C5
http://linked.open...gy/drugbank/InChI	http://linked.opendata.cz/resource/drugbank/property/271B4AB5-363D-11E5-9242-09173F13E4C5
http://linked.open...Molecular-Formula	http://linked.opendata.cz/resource/drugbank/property/271B4AB4-363D-11E5-9242-09173F13E4C5
http://linked.open.../Molecular-Weight	http://linked.opendata.cz/resource/drugbank/property/271B4AB1-363D-11E5-9242-09173F13E4C5
http://linked.open...noisotopic-Weight	http://linked.opendata.cz/resource/drugbank/property/271B4AB2-363D-11E5-9242-09173F13E4C5
http://linked.open...y/drugbank/SMILES	http://linked.opendata.cz/resource/drugbank/property/271B4AB3-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logP	http://linked.opendata.cz/resource/drugbank/property/271B4AAE-363D-11E5-9242-09173F13E4C5
http://linked.open...l/drug/hasATCCode	Asenapine
http://linked.open...nd-Acceptor-Count	http://linked.opendata.cz/resource/drugbank/property/271B4ABB-363D-11E5-9242-09173F13E4C5
http://linked.open...-Bond-Donor-Count	http://linked.opendata.cz/resource/drugbank/property/271B4ABC-363D-11E5-9242-09173F13E4C5
http://linked.open...drugbank/InChIKey	http://linked.opendata.cz/resource/drugbank/property/271B4AB6-363D-11E5-9242-09173F13E4C5
http://linked.open...urface-Area--PSA-	http://linked.opendata.cz/resource/drugbank/property/271B4AB7-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/Polarizability	http://linked.opendata.cz/resource/drugbank/property/271B4AB9-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Refractivity	http://linked.opendata.cz/resource/drugbank/property/271B4AB8-363D-11E5-9242-09173F13E4C5
http://linked.open...atable-Bond-Count	http://linked.opendata.cz/resource/drugbank/property/271B4ABA-363D-11E5-9242-09173F13E4C5
http://linked.open...ugbank/absorption	Cmax, single 5 mg dose = 4 ng/mL (within 1 hour); Bioavailability, sublingual administration = 35%; Bioavailability, oral administration (swallowed) = <2%; Time to steady state, 5 mg = 3 days; Peak plasma concentration occurs within 0.5 to 1.5 hours. Doubling dose of asenapine results in 1.7-fold increase in maximum concentration and exposure. Drinking water within 2-5 minutes post administration of asenapine results in a decrease in exposure. (en)
http://linked.open.../affectedOrganism	Humans and other mammals (en)
http://linked.open...casRegistryNumber	65576-45-6 (en)
http://linked.open...k/Bioavailability	http://linked.opendata.cz/resource/drugbank/property/271B4AC0-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Ghose-Filter	http://linked.opendata.cz/resource/drugbank/property/271B4AC2-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/MDDR-Like-Rule	http://linked.opendata.cz/resource/drugbank/property/271B4AC3-363D-11E5-9242-09173F13E4C5
http://linked.open...k/Number-of-Rings	http://linked.opendata.cz/resource/drugbank/property/271B4ABF-363D-11E5-9242-09173F13E4C5
http://linked.open...siological-Charge	http://linked.opendata.cz/resource/drugbank/property/271B4ABE-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Rule-of-Five	http://linked.opendata.cz/resource/drugbank/property/271B4AC1-363D-11E5-9242-09173F13E4C5
http://linked.open...tional-IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B4AB0-363D-11E5-9242-09173F13E4C5
http://linked.open...-strongest-basic-	http://linked.opendata.cz/resource/drugbank/property/271B4ABD-363D-11E5-9242-09173F13E4C5

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 47 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software